Trexquant Investment Reduces $5M in AbbVie Inc. ($ABBV)
Trexquant Investment trimmed its holdings in AbbVie by 18,177 shares, now holding 77,280 shares.
Key Points
- Trexquant Investment cut its stake in AbbVie Inc. by 18,177 shares, a 19% reduction, leaving it with 77,280 shares valued at $19.58 million.
- AbbVie's stock traded at $253.35 on Monday with a market cap of $447.6 billion and a forward P/E of 15.55.
- Insiders bought shares recently, and analysts like Piper Sandler and Canaccord Genuity maintain a 'buy' rating on the stock.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Trexquant Investment has reduced its holdings in AbbVie Inc. (NYSE:ABBV), according to its latest 13F filing with the SEC. The fund trimmed its position by 18,177 shares, a 19% decrease, bringing its total to 77,280 shares valued at approximately $19.58 million.
Trexquant Investment vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
What Changed in Trexquant Investment's AbbVie Position
Trexquant Investment cut its stake in AbbVie by 18,177 shares, resulting in a 19% reduction. Previously, the fund held 95,457 shares. As of the filing, Trexquant's position in AbbVie is 77,280 shares, worth about $19.58 million.
Other Institutional Activity in AbbVie
Several other major funds also made moves in AbbVie. BlackRock, Inc. reduced its holdings slightly by 476,418 shares to hold 150,698,125 shares, valued at $32.78 billion. Vanguard Capital Management LLC opened a new position with 114,880,324 shares worth $24.99 billion. Meanwhile, State Street Corp increased its holdings by 276,585 shares to 81,217,516 shares, valued at $17.66 billion. JPMorgan Chase & Co added 4,348,368 shares, ending with 56,741,691 shares worth $12.09 billion. Geode Capital Management, LLC also increased its stake by 2,107,601 shares to 46,737,581 shares, valued at $10.14 billion.
AbbVie Inc. Stock Down 1.1%
On Monday, shares of NYSE:ABBV traded near $253.35. AbbVie has a market cap of about $447.6 billion, with a forward P/E ratio of 15.55 and a beta of 0.309. The stock's 52-week range is between $181.75 and $253.35. Its 50-day moving average is $214.78, while the 200-day moving average is $221.26.
$ABBV stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
AbbVie reported revenue of $62.82 billion, reflecting a growth of 12.4%. The company achieved an EPS of $2.05 with a net margin of 5.79%. AbbVie is expected to announce its next earnings on July 31, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
4 analysts raised price targets.
-
EPS & revenue
EPS met estimates. Revenue met estimates.
-
Profit surprise
EBITDA missed by 42 percent. Operating income missed by 72 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
4 target raises.
-
Earnings quality
Gross margin up 1.9 points. Operating margin up 3.6 points. Positive free cash flow.
Earnings Call Summary
AbbVie delivered strong first quarter results with $15 billion in sales and earnings per share of $2.65, beating expectations. Skyrizi sales hit $4.5 billion with 29 percent growth in psoriasis and inflammatory bowel disease markets. Rinvoq brought in $2.1 billion with 20 percent growth across rheumatology and gastroenterology, and the company is preparing to launch the drug in alopecia areata and vitiligo later this year.
Guidance The company raised full year earnings per share guidance to between $14.08 and $14.28, up $0.12. They now expect about $67.3 billion in total sales for the year. They also raised guidance for second quarter to about $16.7 billion in revenue and earnings per share between $3.74 and $3.78.
Fine but not compelling. Acceptable results that likely do not create a meaningful forward reset.
Dividend
AbbVie pays an annual dividend rate of $6.92, yielding 2.73%. The company's dividend payout ratio stands at 325.98%.
Insider Buying and Selling at AbbVie Inc.
Several insiders made purchases on May 8, 2026. Frederick Waddell, William Burnside, Thomas Falk, Roxanne Austin, Edward Rapp, and Brett Hart each bought 1,118 shares. These transactions were not part of a 10b5-1 plan.
Analysts Set New Price Targets
On June 23, 2026, Piper Sandler reiterated its 'buy' rating with a price target of $298. Canaccord Genuity maintained a 'buy' rating with a target of $273. Evercore ISI Group also maintained its 'buy' rating with a target of $235 on May 15, 2026. The consensus among 29 analysts is a 'buy', with a mean target price of $254.38.
About AbbVie Inc.
AbbVie Inc. is a biopharmaceutical company headquartered in North Chicago, Illinois. It focuses on the development and sale of medicines and therapies worldwide, offering treatments for autoimmune diseases, cancers, and neurological conditions, among others. The company, led by CEO Scott T. Reents, employs around 57,000 people.
Bottom Line
Trexquant Investment's decision to reduce its stake in AbbVie by 19% reflects its latest portfolio strategy as per the 13F filing. Investors often track such moves for insights, though these filings are backward-looking and may not indicate current positions. AbbVie remains a significant player in the healthcare sector, with strong institutional interest and positive analyst sentiment.
Get AbbVie Inc. alerts
New 13F filings, insider trades, and analyst moves on $ABBV, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.